CTRI/2023/09/057712招募中3 期
Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy: A Randomized, Double Blind, Placebo Controlled Trial - NI
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Liver cirrhosis patients between 18 to 70 yrs with low risk esophageal varices and HOD (osteoporosis/osteopenia will be enrolled).
- •2.Patient and attendants willing to give informed consent
排除标准
- •1.Age <18 years and > 70 years
- •2.Patients with prior history of fracture
- •3.History of upper GI bleed in last 2 months
- •4.Patients with post EVL ulcers
- •5.High risk esophageal varices or gastric varices without endoscopic treatment.
- •6.Active peptic ulcer
- •7.Severe vascular ectasia
- •8.Esophageal stricture
- •9.Achalasia
- •10.Creatinine clearance below 30ml/min
- •11.Malignancy(except HCC)
- •12.Hyperparathyroidism
- •13.Patients using NSAIDs, corticosteroids ,anticoagulants or ongoing alcohol beverages
- •14.Bisphosphonate hypersensitivity/Oral bisphosphonate within 12 months
- •15.Grade 2/3 ascites
- •16.Hepatic encephalopathy(Grade 3 &4)
- •17.Critically ill patients
- •18.Post LT patients
- •19.HRT within 6 mths
- •20.Pregnant and lactating women
- •21.Patient with bleeding disorders
研究者
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and safety of ibandronate as treatment of metastatic bone pain in patients with different tumor types. A randomised phase II studyEUCTR2004-002131-12-ITROCHE
已完成
4 期
Efficacy of Itraconazole in the treatment of Seborrheic Dermatitis.Seborrhoeic dermatitis.L21 Seborrhoeic dermatitis Excl: Seborrhoea capitisL21.8 Other seborrhoeic dermatitis L21.9 Seborrhoeic dermatitis, unspecifiedIRCT2012091510842N1Tehran University of Medical Sciences68
招募中
2 期
Evaluation of intravenous pamidronate & oral alendronate on bone marrow density in ?patients with major and intermedia thalassemiaIRCT2017070420258N51Vice chancellor for research, Arak University of Medical Sciences40
进行中（未招募）
不适用
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolicdysfunctioModerate to severe chronic heart failure and reduced left ventricular ejection fractionMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2012-001689-13-EEInstitut de Recherches Internationales Servier700
进行中（未招募）
不适用
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolicdysfunctioModerate to severe chronic heart failure and reduced left ventricular ejection fractionMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-001689-13-HUInstitut de Recherches Internationales Servier700